Immunome (IMNM) Projected to Announce Quarterly Earnings on Thursday

Immunome (NASDAQ:IMNM) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Immunome to post earnings of ($0.6124) per share and revenue of $0.15 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14). On average, analysts expect Immunome to post ($2.48) EPS for the current fiscal year and ($2.76) EPS for the next fiscal year.

Immunome Stock Performance

NASDAQ:IMNM opened at $18.76 on Thursday. Immunome has a 52 week low of $14.64 and a 52 week high of $30.06. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -7.42 and a beta of 2.55. The firm’s 50-day simple moving average is $22.87 and its 200 day simple moving average is $22.49.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $35.00 price objective on shares of Immunome in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a report on Tuesday. Wall Street Zen downgraded shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research report on Thursday, October 15th. Finally, Citigroup reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Immunome has an average rating of “Moderate Buy” and a consensus target price of $34.25.

Insider Activity

In related news, insider Jack Higgins sold 13,200 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the sale, the insider directly owned 65,050 shares of the company’s stock, valued at $1,647,066. This trade represents a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the completion of the sale, the insider directly owned 50,366 shares in the company, valued at $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 223,368 shares of company stock worth $5,747,142. Insiders own 7.21% of the company’s stock.

About Immunome

Immunome, Inc (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company’s research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations.